317 related articles for article (PubMed ID: 17405908)
21. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
[TBL] [Abstract][Full Text] [Related]
22. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
[TBL] [Abstract][Full Text] [Related]
23. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection.
Ebihara T; Masuda H; Akazawa T; Shingai M; Kikuta H; Ariga T; Matsumoto M; Seya T
Int Immunol; 2007 Oct; 19(10):1145-55. PubMed ID: 17878262
[TBL] [Abstract][Full Text] [Related]
24. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
[TBL] [Abstract][Full Text] [Related]
25. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70.
Bae JH; Kim JY; Kim MJ; Chang SH; Park YS; Son CH; Park SJ; Chung JS; Lee EY; Kim SH; Kang CD
J Immunother; 2010 May; 33(4):391-401. PubMed ID: 20386467
[TBL] [Abstract][Full Text] [Related]
26. Transfer of the human NKG2D ligands UL16 binding proteins (ULBP) 1-3 is related to lytic granule release and leads to ligand retransfer and killing of ULBP-recipient natural killer cells.
López-Cobo S; Romera-Cárdenas G; García-Cuesta EM; Reyburn HT; Valés-Gómez M
Immunology; 2015 Sep; 146(1):70-80. PubMed ID: 25980678
[TBL] [Abstract][Full Text] [Related]
27. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
28. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
29. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
Kim Y; Born C; Bléry M; Steinle A
Front Immunol; 2020; 11():960. PubMed ID: 32582150
[TBL] [Abstract][Full Text] [Related]
30. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.
Sutherland CL; Rabinovich B; Chalupny NJ; Brawand P; Miller R; Cosman D
Blood; 2006 Aug; 108(4):1313-9. PubMed ID: 16621962
[TBL] [Abstract][Full Text] [Related]
31. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
[TBL] [Abstract][Full Text] [Related]
32. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
[TBL] [Abstract][Full Text] [Related]
33. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
Ge X; Li CR; Yang J; Wang GB
Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
[TBL] [Abstract][Full Text] [Related]
34. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
35. The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity.
Desimio MG; Giuliani E; Doria M
Virology; 2017 Oct; 510():9-21. PubMed ID: 28689087
[TBL] [Abstract][Full Text] [Related]
36. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
37. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.
Soriani A; Zingoni A; Cerboni C; Iannitto ML; Ricciardi MR; Di Gialleonardo V; Cippitelli M; Fionda C; Petrucci MT; Guarini A; Foà R; Santoni A
Blood; 2009 Apr; 113(15):3503-11. PubMed ID: 19098271
[TBL] [Abstract][Full Text] [Related]
38. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
Mei JZ; Guo KY; Wei HM; Song CY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
[TBL] [Abstract][Full Text] [Related]
39. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
[TBL] [Abstract][Full Text] [Related]
40. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.
Okita R; Yukawa T; Nojima Y; Maeda A; Saisho S; Shimizu K; Nakata M
Cancer Immunol Immunother; 2016 May; 65(5):499-509. PubMed ID: 26940474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
